Want to see RAPP full AI Analyst Report?
RAPP Stock Chart & Stats
$40.68
$1.42(3.49%)
At close: 4:00 PM EDT
$40.68
$1.42(3.49%)
Day’s Range― - ―
52-Week Range$13.62 - $44.28
Previous CloseN/A
Volume230.44K
Average Volume (3M)404.29K
Market Cap
$2.01B
Enterprise Value$1.01K
Total Cash (Recent Filing)$476.78M
Total Debt (Recent Filing)$10.80M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Aug 06, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding47,826,927
10 Day Avg. Volume321,428
30 Day Avg. Volume404,290
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-16.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$56.17Price Target Upside38.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-3.45
Revenue Forecast (FY)$20.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity ratio and a rebuilt equity base provide durable financial flexibility to fund clinical programs, absorb trial delays, and pursue partnerships without immediate liquidity distress. This reduces bankruptcy risk and supports multi-quarter R&D investment horizons.
Emerging Revenue InflectionThe emergence of TTM revenues signals initial commercial or milestone inflows, reducing pure binary clinical risk and indicating early monetization of assets or partnerships. Over 2-6 months this can modestly improve runway dynamics and inform business development strategies.
Positive Phase 2a Clinical ReadoutRobust Phase 2a follow-up data for RAP-219 strengthens the development thesis, raising the probability of a successful Phase 3 program and making the asset more attractive for partnerships or licensing. Clinically durable efficacy and tolerability are long-term value drivers for regulatory and commercial viability.
Bears Say
High Cash BurnSustained negative operating and free cash flow at ~-$80M TTM creates an ongoing funding requirement that will likely necessitate additional capital raises or partnerships. This elevates dilution and can force reprioritization of programs, constraining strategic optionality over the medium term.
Large Ongoing Net LossesMaterial and persistent net losses reflect that the cost base far outstrips current revenues, delaying path to profitability. Until revenues scale or costs are materially reduced, margins will remain negative, making long-term sustainability contingent on successful clinical/commercial milestones or external funding.
Clinical-stage, Concentrated Pipeline RiskBeing a clinical-stage, CNS-focused biopharma with a concentrated pipeline means outcomes hinge on a small number of trials (notably RAP-219). Binary clinical or regulatory setbacks can materially impair revenue visibility and funding prospects, increasing strategic and execution risk over months.
Rapport Therapeutics, Inc. News
RAPP FAQ
What was Rapport Therapeutics, Inc.’s price range in the past 12 months?
Rapport Therapeutics, Inc. lowest stock price was $13.62 and its highest was $44.28 in the past 12 months.
What is Rapport Therapeutics, Inc.’s market cap?
Rapport Therapeutics, Inc.’s market cap is $2.01B.
When is Rapport Therapeutics, Inc.’s upcoming earnings report date?
Rapport Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 7 days.
How were Rapport Therapeutics, Inc.’s earnings last quarter?
Rapport Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.605 by $0.185.
Is Rapport Therapeutics, Inc. overvalued?
According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued.
Does Rapport Therapeutics, Inc. pay dividends?
Rapport Therapeutics, Inc. does not currently pay dividends.
What is Rapport Therapeutics, Inc.’s EPS estimate?
Rapport Therapeutics, Inc.’s EPS estimate is -0.96.
How many shares outstanding does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. has 47,826,927 shares outstanding.
What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?
Rapport Therapeutics, Inc. reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.605. Following the earnings report the stock price went up 7.744%.
Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RAPP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapport Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.17 (38.07% Upside)
$56.17 (38.07% Upside)
Blogger Sentiment
Bullish
RAPP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
64.74%
Trailing 12-Months
Company Description
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Stock 12 Month Forecast
Average Price Target
$56.17
▲(38.07% Upside)
Technical Analysis
Ownership Overview
22.51% Insiders
24.40% Mutual Funds
0.14% Other Institutional Investors
44.05% Public Companies and
Individual Investors